Wockhardt（WOCKPHARMA）株式概要ウォックハルト・リミテッドは製薬およびバイオテクノロジー企業で、インド、米国、英国、スイス、アイルランド、ロシア、ヨーロッパおよび国際的に医薬品、薬用植物、化学製品を製造、販売している。 詳細WOCKPHARMA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績2/6財務の健全性4/6配当金0/6報酬今年は黒字化を達成 リスク分析財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るWOCKPHARMA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹1.58k66.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6b45b2016201920222025202620282031Revenue ₹36.0bEarnings ₹2.3bAdvancedSet Fair ValueView all narrativesWockhardt Limited 競合他社Neuland LaboratoriesSymbol: BSE:524558Market cap: ₹213.4bPfizerSymbol: NSEI:PFIZERMarket cap: ₹213.7bGranules IndiaSymbol: BSE:532482Market cap: ₹186.2bJ. B. Chemicals & PharmaceuticalsSymbol: BSE:506943Market cap: ₹352.6b価格と性能株価の高値、安値、推移の概要Wockhardt過去の株価現在の株価₹1,575.4052週高値₹1,868.8052週安値₹1,086.70ベータ0.771ヶ月の変化9.32%3ヶ月変化14.03%1年変化17.51%3年間の変化814.87%5年間の変化139.26%IPOからの変化483.88%最新ニュース分析記事 • May 11Wockhardt's (NSE:WOCKPHARMA) Strong Earnings Are Of Good QualityWhen companies post strong earnings, the stock generally performs well, just like Wockhardt Limited's ( NSE:WOCKPHARMA...Reported Earnings • May 06Full year 2026 earnings released: EPS: ₹13.12 (vs ₹3.00 loss in FY 2025)Full year 2026 results: EPS: ₹13.12 (up from ₹3.00 loss in FY 2025). Revenue: ₹34.8b (up 15% from FY 2025). Net income: ₹2.13b (up ₹2.60b from FY 2025). Profit margin: 6.1% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 09Wockhardt Limited Files Marketing Authorisation Application for WCK 5222 with European Medicines AgencyWockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026. The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries-Iceland, Liechtenstein, and Norway-covering a total of 30 countries. Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA. Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections. Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation.分析記事 • Dec 07Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 0.09% per year over the past 5 years.分析記事 • Nov 10Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With RevenuesWockhardt Limited's ( NSE:WOCKPHARMA ) price-to-sales (or "P/S") ratio of 7.2x may look like a poor investment...最新情報をもっと見るRecent updates分析記事 • May 11Wockhardt's (NSE:WOCKPHARMA) Strong Earnings Are Of Good QualityWhen companies post strong earnings, the stock generally performs well, just like Wockhardt Limited's ( NSE:WOCKPHARMA...Reported Earnings • May 06Full year 2026 earnings released: EPS: ₹13.12 (vs ₹3.00 loss in FY 2025)Full year 2026 results: EPS: ₹13.12 (up from ₹3.00 loss in FY 2025). Revenue: ₹34.8b (up 15% from FY 2025). Net income: ₹2.13b (up ₹2.60b from FY 2025). Profit margin: 6.1% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 09Wockhardt Limited Files Marketing Authorisation Application for WCK 5222 with European Medicines AgencyWockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026. The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries-Iceland, Liechtenstein, and Norway-covering a total of 30 countries. Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA. Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections. Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation.分析記事 • Dec 07Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 0.09% per year over the past 5 years.分析記事 • Nov 10Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With RevenuesWockhardt Limited's ( NSE:WOCKPHARMA ) price-to-sales (or "P/S") ratio of 7.2x may look like a poor investment...Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.81 (vs ₹1.47 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹4.81 (up from ₹1.47 loss in 2Q 2025). Revenue: ₹8.03b (flat on 2Q 2025). Net income: ₹780.0m (up ₹1.00b from 2Q 2025). Profit margin: 9.7% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Aug 02Here's Why Wockhardt Limited's (NSE:WOCKPHARMA) CEO May Deserve A RaiseKey Insights Wockhardt will host its Annual General Meeting on 8th of August Salary of ₹24.1m is part of CEO Murtaza...Reported Earnings • Jul 18Full year 2025 earnings released: ₹3.00 loss per share (vs ₹32.10 loss in FY 2024)Full year 2025 results: ₹3.00 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.4b (up 7.2% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 17Wockhardt Limited, Annual General Meeting, Aug 08, 2025Wockhardt Limited, Annual General Meeting, Aug 08, 2025, at 15:30 Indian Standard Time.お知らせ • Jul 16+ 3 more updatesWockhardt Limited to Report Fiscal Year 2026 Results on May 30, 2026Wockhardt Limited announced that they will report fiscal year 2026 results on May 30, 2026New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).分析記事 • Jun 11Wockhardt Limited's (NSE:WOCKPHARMA) 26% Price Boost Is Out Of Tune With RevenuesWockhardt Limited ( NSE:WOCKPHARMA ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jun 02Does Wockhardt (NSE:WOCKPHARMA) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • May 31Full year 2025 earnings released: ₹3.02 loss per share (vs ₹32.10 loss in FY 2024)Full year 2025 results: ₹3.02 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.7b (up 8.6% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 23Wockhardt Limited to Report Q4, 2025 Results on May 29, 2025Wockhardt Limited announced that they will report Q4, 2025 results on May 29, 2025New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 18% per year over the past 5 years.お知らせ • Apr 07Wockhardt Looks to Exit US Generics BizWockhardt Limited (NSEI:WOCKPHARMA) is planning to exit the US generics business. Meanwhile, US consumers will have to bear the burden of tariffs, NDTV Profit reported. Habil Khorakiwala, Chairperson of Wockhardt, said, "There is a price pressure on US consumer and healthcare provider in the US. "As far as Wockhardt is concerned, we have around 5% presence in the US and we have planned to exit the US generic business," he said. Commenting on the pharmaceutical industry’s ability to manufacture products in the US, he said, “…will be very, very difficult for pharma to manufacture all products in the US because it will take several years to do that”. This comes amid US President Donald Trump's recent announcement on his administration's intention to impose unprecedented tariffs on pharmaceutical imports, signalling a shift from earlier exemptions under his reciprocal tariff policy. He clarified that pharmaceuticals would be treated as a separate category, with official announcements expected soon. This announcement follows his broader tariff measures, including a 26% duty on Indian imports and a universal 10% tariff on other goods, which were initially exempting pharmaceuticals.分析記事 • Apr 02There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 25% Price JumpThose holding Wockhardt Limited ( NSE:WOCKPHARMA ) shares would be relieved that the share price has rebounded 25% in...Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹0.91 (vs ₹5.75 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.91 (up from ₹5.75 loss in 3Q 2024). Revenue: ₹7.29b (up 4.0% from 3Q 2024). Net income: ₹140.0m (up ₹970.0m from 3Q 2024). Profit margin: 1.9% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 03Wockhardt Limited to Report Q3, 2025 Results on Feb 07, 2025Wockhardt Limited announced that they will report Q3, 2025 results on Feb 07, 2025New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).分析記事 • Dec 17What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling YouDespite an already strong run, Wockhardt Limited ( NSE:WOCKPHARMA ) shares have been powering on, with a gain of 31% in...Reported Earnings • Nov 14Second quarter 2025 earnings released: ₹1.47 loss per share (vs ₹5.37 loss in 2Q 2024)Second quarter 2025 results: ₹1.47 loss per share (improved from ₹5.37 loss in 2Q 2024). Revenue: ₹8.18b (up 8.6% from 2Q 2024). Net loss: ₹220.0m (loss narrowed 71% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.お知らせ • Nov 09Wockhardt Limited to Report First Half, 2025 Results on Nov 13, 2024Wockhardt Limited announced that they will report first half, 2025 results on Nov 13, 2024お知らせ • Nov 07Wockhardt Limited has filed a Follow-on Equity Offering.Wockhardt Limited has filed a Follow-on Equity Offering. Security Name: Equity Shares Security Type: Common Stock Price(minimum): INR 1162.25 Transaction Features: Regulation S; Subsequent Direct Listing分析記事 • Nov 02Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch UpWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 29% gain in the last month...お知らせ • Oct 12Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control OrganizationThe Subject Expert Committee (SEC) of Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has provided a favourable recommendation for Wockhardt's novel antibiotic MiqnafTM (nafithromycin) discovered and developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults. The SEC recommendation is based on CDSCO's comprehensive review of product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over last 15 years. A positive opinion from SEC of CDSCO would pave the way for gaining DCGI's final approval for MiqnafTM. MiqnafTM is globally, 1st-ever, Once-a-Day (OD) 3-days-only treatment for CABP patients including those caused by multi-drug resistant (MDR) bugs. The attractive feature of MiqnafTM is that it is highly active against azithromycin and amoxicillin/clavulanate resistant Pneumococci, as well as entire range of pathogens involved in such infections and thus offering a monotherapy option. Earlier, a lung penetration study conducted in the US demonstrated best-in-class lung concentrations of MiqnafTM enabling to evolve a convenient, compliance-friendly treatment for respiratory infections. MiqnafTM is expected to play a significant role in offering a reliable treatment option in the community and thus would obviate the need of hospitalization. Community-acquired pneumonia is the most common infection leading to hospitalization and deaths. Children and older adults are particularly vulnerable. Globally, 2.4 million annual deaths are caused by lower respiratory tract infections. India contributes to 23% of global community pneumonia burden.お知らせ • Oct 07Wockhardt's WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I StudyWockhardt announced advancing the development of several new antibiotics aimed at combating difficult-to-treat drug-resistant bacterial infections that drive anti-microbial resistance (AMR) linked mortality and morbidity. Recently, one of its unique once-a-day, -lactam enhancer based MDR-active antibiotic, WCK 6777 (Ertapenem/Zidebactam) has successfully completed a Phase I study conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in US. Recognizing the therapeutic potential of WCK 6777 for infections caused by MDR Gram negative pathogens, DMID of NIH had selected this drug for Phase I studies. Zidebactam has already demonstrated promising safety profile in Phase I and on-going Phase II & III studies in combination with Cefepime (WCK 5222). Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI). WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient- parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections. Phase I study of WCK 6777 involved 52 participants and was designed as a double-blind, placebo-controlled, multiple-ascending dose trial in healthy volunteers. The trial rigorously assessed the safety and pharmacokinetics of WCK 6777, administering intravenous doses higher than the anticipated clinical dose over a period of 7 days. Results demonstrated a promising safety profile, with WCK 6777 (up to 3 grams + 3 grams daily) being well-tolerated, and no serious or unexpected adverse events reported. None of the subjects withdrew or were discontinued from the study due to treatment-related adverse events. Pharmacokinetic analysis revealed consistent exposure levels of both ertapenem and zidebactam, with no significant interactions when co-administered daily for the duration of the study. The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II /III clinical trials. Globally, incidence of UTI were 404.61 million with 236,790 deaths estimated in 2019. It is estimated that 1 in 100 of US adults will experience a cUTI each year, resulting in approximately 2.8 million cUTI cases and annualized total US costs in excess of $6 billion. There are 600,000 hospital admissions among adults for cUTIs each year in the United States with each episode costing an average of $9,441. Emerging therapeutic role of WCK 6777 makes it uniquely positioned to cater to the vast unmet need in the management of infections outside the hospital. About Ertapenem/Zidebactam (WCK 6777): Through independent studies, WCK 6777 is shown to be active against several carbapenem- resistant Gram-negative pathogens such as E. coli and Klebsiella including those producing metallo -lactamases, often encountered in community as well as hospital infections such as urinary tract infections (UTI). Other recently approved antibiotics do not address this issue. Owing to its activity against CDC/WHO/FDA categorized priority pathogens, WCK 6777 was granted a qualified infectious disease product (QIDP) designation in 2020 by U.S. FDA. About Wockhardt's New Drug Discovery portfolio: Over the period of 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA. Wockhardt's flagship novel mechanism based antibiotic, Zaynich (Cepefime/Zidebactam), designed to target extreme-drug resistant Gram negative infections, is undergoing a global Phase 3 study. Zaynich has already saved lives of >35 critically ill patients under compassionate use over last one year and is also being evaluated in a clinical study involving patients with documented meropenem-resistant infections. Clinical and Laboratory Standards Institute (CLSI), US has granted it a susceptibility breakpoint of 64 mg/L for 10 Gram negative pathogens showing high resistance rates, signifying strong potential to cover all the clinically important, extreme drug resistant Gram negative pathogens in seriously ill patients.分析記事 • Aug 20What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling YouWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 27% gain in the last month...Reported Earnings • Aug 10First quarter 2025 earnings released: ₹0.95 loss per share (vs ₹9.28 loss in 1Q 2024)First quarter 2025 results: ₹0.95 loss per share (improved from ₹9.28 loss in 1Q 2024). Revenue: ₹7.69b (up 19% from 1Q 2024). Net loss: ₹140.0m (loss narrowed 90% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.お知らせ • Aug 05Wockhardt Limited to Report Q1, 2025 Results on Aug 09, 2024Wockhardt Limited announced that they will report Q1, 2025 results on Aug 09, 2024分析記事 • Jul 27Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Jun 30Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedWockhardt Limited ( NSE:WOCKPHARMA ) shares have had a really impressive month, gaining 28% after a shaky period...分析記事 • Jun 22Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO CompensationKey Insights Wockhardt to hold its Annual General Meeting on 28th of June CEO Murtaza Khorakiwala's total compensation...お知らせ • Jun 08+ 1 more updateWockhardt Limited, Annual General Meeting, Jun 28, 2024Wockhardt Limited, Annual General Meeting, Jun 28, 2024, at 11:00 Indian Standard Time.お知らせ • May 30Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) DirectorWockhardt Limited announced at the board meeting held on May 28, 2024, approved appointment of Amb. Ahmad Javed (DIN: 08668304) as an Additional (Independent) Director of the Company with effect from 28th May, 2024 and will hold office as an Additional Director of the Company until the upcoming 25th Annual General Meeting of the Company. Amb. Ahmad Javed, aged 68 years, is a distinguished former IPS officer of the 1980 batch Maharashtra cadre and a seasoned diplomat. With a robust educational foundation from St. Stephen's College, Delhi University, he has dedicated nearly four decades to law enforcement and public service. During his stint, Amb. Ahmad served as Commissioner of Police in Solapur City, New Mumbai, and Mumbai, and as Joint Commissioner of Police (Law & Order) in Mumbai. His notable diplomatic tenure includes serving as the Ambassador of India to Saudi Arabia from 2016 to2019. Amb. Ahmad's extensive experience encompasses law and order maintenance, crisis handling and management, Administration & HR, international relations, strategy and policy formulation and conflict resolution. Amb. Ahmad has been honoured with the Police Medal for Meritorious Service, President's Police Medal for Distinguished Service and Director General's Insignia. Currently, he contributes his expertise as an advisor and Independent Director to various organizations.Reported Earnings • May 29Full year 2024 earnings released: ₹32.05 loss per share (vs ₹38.80 loss in FY 2023)Full year 2024 results: ₹32.05 loss per share (improved from ₹38.80 loss in FY 2023). Revenue: ₹28.8b (up 8.7% from FY 2023). Net loss: ₹4.63b (loss narrowed 17% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • May 23Wockhardt Limited to Report Q4, 2024 Results on May 28, 2024Wockhardt Limited announced that they will report Q4, 2024 results on May 28, 2024お知らせ • Apr 04Wockhardt Limited Announces Cessation of Independent DirectorsWockhardt Limited announced that Dr. Sanjaya Baru, Mr. D S Brar and Mr. Aman Mehta ceased to be an Independent Directors of the Company on March 31, 2024, upon completion of their second term of five (5) consecutive years .お知らせ • Mar 28Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion.Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 9,285,163 Price\Range: INR 517 Transaction Features: Regulation S; Subsequent Direct ListingNew Risk • Mar 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.6% operating cash flow to total debt). Earnings have declined by 24% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).お知らせ • Mar 22Wockhardt Limited has filed a Follow-on Equity Offering.Wockhardt Limited has filed a Follow-on Equity Offering. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Subsequent Direct Listing分析記事 • Feb 21Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%Despite an already strong run, Wockhardt Limited ( NSE:WOCKPHARMA ) shares have been powering on, with a gain of 29% in...Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹5.75 loss per share (vs ₹6.62 loss in 3Q 2023)Third quarter 2024 results: ₹5.75 loss per share (improved from ₹6.62 loss in 3Q 2023). Revenue: ₹7.09b (up 1.4% from 3Q 2023). Net loss: ₹830.0m (loss narrowed 14% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.分析記事 • Dec 19There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price JumpWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 28% gain in the last month...New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).Reported Earnings • Nov 15Second quarter 2024 earnings released: ₹5.37 loss per share (vs ₹13.15 loss in 2Q 2023)Second quarter 2024 results: ₹5.37 loss per share (improved from ₹13.15 loss in 2Q 2023). Revenue: ₹7.77b (up 14% from 2Q 2023). Net loss: ₹770.0m (loss narrowed 59% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.分析記事 • Oct 14There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.4x Wockhardt Limited ( NSE:WOCKPHARMA ) is a stock worth...Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Independent Director Amelia Fernandes was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 05Wockhardt Limited to Report Q1, 2024 Results on Aug 14, 2023Wockhardt Limited announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Jul 24Wockhardt Limited, Annual General Meeting, Aug 14, 2023Wockhardt Limited, Annual General Meeting, Aug 14, 2023, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon; to appoint a Director in place of Ms. Zahabiya Khorakiwala, who retires from office by rotation and, being eligible, offers herself for re-appointment; to consider ratification of remuneration payable to the Cost Auditors for the Financial Year 2023-24; to consider appointment of Ms. Amelia Fernandes as an Independent Director of the Company; to consider approval for re-appointment of Dr. Huzaifa Khorakiwala as an Executive Director and Fixation of Remuneration; and to consider approval for re-appointment of Dr. Murtaza Khorakiwala as Managing Director and Fixation of Remuneration.お知らせ • May 20Wockhardt Limited to Report Q4, 2023 Results on May 26, 2023Wockhardt Limited announced that they will report Q4, 2023 results on May 26, 2023Reported Earnings • Feb 14Third quarter 2023 earnings released: ₹6.62 loss per share (vs ₹0.61 loss in 3Q 2022)Third quarter 2023 results: ₹6.62 loss per share (further deteriorated from ₹0.61 loss in 3Q 2022). Revenue: ₹7.01b (down 18% from 3Q 2022). Net loss: ₹960.0m (loss widened ₹892.2m from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Feb 04Wockhardt Limited to Report Q3, 2023 Results on Feb 13, 2023Wockhardt Limited announced that they will report Q3, 2023 results on Feb 13, 2023Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 06Second quarter 2023 earnings released: ₹13.15 loss per share (vs ₹3.03 profit in 2Q 2022)Second quarter 2023 results: ₹13.15 loss per share (down from ₹3.03 profit in 2Q 2022). Revenue: ₹7.36b (down 15% from 2Q 2022). Net loss: ₹1.89b (down ₹2.23b from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.分析記事 • Jun 23Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Jun 02Full year 2022 earnings releasedFull year 2022 results: Revenue: (down 100% from FY 2021). Net income: (up ₹2.99b from FY 2021). Profit margin: (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Feb 18Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)Does the February share price for Wockhardt Limited ( NSE:WOCKPHARMA ) reflect what it's really worth? Today, we will...Reported Earnings • Feb 01Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: ₹0.61 loss per share (down from ₹1.38 profit in 3Q 2021). Revenue: ₹8.56b (up 12% from 3Q 2021). Net loss: ₹67.8m (down 145% from profit in 3Q 2021). Revenue missed analyst estimates by 7.3%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • Jan 04Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹3.03 (vs ₹0.32 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹8.62b (up 21% from 2Q 2021). Net income: ₹335.3m (up ₹299.8m from 2Q 2021). Profit margin: 3.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 02Board Member recently bought ₹4.4m worth of stockOn the 25th of August, Akhilesh Krishna Gupta bought around 10k shares on-market at roughly ₹439 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹22m more in shares than they bought in the last 12 months.分析記事 • Jul 26Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time BeingAs many shareholders of Wockhardt Limited ( NSE:WOCKPHARMA ) will be aware, they have not made a gain on their...Executive Departure • Jul 23Company Secretary & Compliance Officer Gajanand Sahu has left the companyOn the 22nd of July, Gajanand Sahu's tenure as Company Secretary & Compliance Officer ended after 1.2 years in the role. We don't have any record of a personal shareholding under Gajanand's name. Gajanand is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.38 years.Reported Earnings • Jul 10Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: ₹27.1b (down 4.8% from FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Jun 18Insider recently sold ₹20m worth of stockOn the 14th of June, Mahesh Patel sold around 30k shares on-market at roughly ₹658 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.Reported Earnings • May 30Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)The company reported a poor full year result with increased losses and weaker control over costs, although revenues were flat. Full year 2021 results: Revenue: ₹28.4b (flat on FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • May 18Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)In this article we are going to estimate the intrinsic value of Wockhardt Limited ( NSE:WOCKPHARMA ) by taking the...Reported Earnings • Jan 30Third quarter 2021 earnings released: EPS ₹1.38 (vs ₹0.87 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: ₹8.65b (flat on 3Q 2020). Net income: ₹152.4m (up 58% from 3Q 2020). Profit margin: 1.8% (up from 1.1% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.分析記事 • Jan 26Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)In this article we are going to estimate the intrinsic value of Wockhardt Limited ( NSE:WOCKPHARMA ) by taking the...Is New 90 Day High Low • Dec 30New 90-day high: ₹551The company is up 82% from its price of ₹303 on 01 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.Recent Insider Transactions • Dec 17Insider recently sold ₹1.6m worth of stockOn the 11th of December, Mahesh Patel sold around 3k shares on-market at roughly ₹536 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Is New 90 Day High Low • Dec 08New 90-day high: ₹487The company is up 73% from its price of ₹281 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.分析記事 • Dec 01What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?Murtaza Khorakiwala has been the CEO of Wockhardt Limited ( NSE:WOCKPHARMA ) since 2009, and this article will examine...Is New 90 Day High Low • Nov 20New 90-day high: ₹393The company is up 22% from its price of ₹322 on 21 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.株主還元WOCKPHARMAIN PharmaceuticalsIN 市場7D1.9%-0.07%0.5%1Y17.5%10.3%-0.5%株主還元を見る業界別リターン: WOCKPHARMA過去 1 年間で10.3 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: WOCKPHARMA過去 1 年間で-0.5 % の収益を上げたIndian市場を上回りました。価格変動Is WOCKPHARMA's price volatile compared to industry and market?WOCKPHARMA volatilityWOCKPHARMA Average Weekly Movement7.1%Pharmaceuticals Industry Average Movement6.7%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: WOCKPHARMA 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: WOCKPHARMAの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19672,296Murtaza Khorakiwalawww.wockhardt.com医薬品・バイオテクノロジー企業であるウォックハルト・リミテッドは、インド、米国、英国、スイス、アイルランド、ロシア、欧州、および国際的に医薬品、薬用植物、化学製品の製造・販売を行っている。同社は、敗血症および病院・人工呼吸器関連肺炎の治療薬として臨床第3相試験中のWCK5222、ESBL感染症の治療薬として臨床第3相試験中のWCK4282、グラム陰性菌感染症の治療薬として臨床第1相試験中のWCK6777、市中肺炎の治療薬として臨床第3相試験中のWCK4873など、適格な感染症治療薬を開発している。また、速効型および長時間作用型インスリンアナログ、濃縮インスリン、GLP1アナログ、ヘモポエチン、バイオベッターおよび新規製品、送達デバイスも提供している。また、B型肝炎ワクチンBiovac-B、遺伝子組換えヒトエリスロポエチン製剤WEPOX、遺伝子組換えヒトインスリン製剤WOSULIN、遺伝子組換えインスリングラルギン製剤GLARITUSを開発・販売している。また、受託製造サービス、医薬品原薬の提供も行っている。ウォックハルト社は1967年に設立され、本社はインドのムンバイにある。もっと見るWockhardt Limited 基礎のまとめWockhardt の収益と売上を時価総額と比較するとどうか。WOCKPHARMA 基礎統計学時価総額₹255.99b収益（TTM）₹2.13b売上高(TTM)₹33.73b120.2xPER（株価収益率7.6xP/SレシオWOCKPHARMA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計WOCKPHARMA 損益計算書（TTM）収益₹33.73b売上原価₹11.32b売上総利益₹22.41bその他の費用₹20.28b収益₹2.13b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）13.11グロス・マージン66.44%純利益率6.31%有利子負債／自己資本比率40.2%WOCKPHARMA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 16:08終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Wockhardt Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Aarthisundari Jayakumar360 ONE Capital Market Private LimitedSriraam RathiAnand Rathi Shares and Stock Brokers Limitednull nullAnand Rathi Shares and Stock Brokers Limited10 その他のアナリストを表示
分析記事 • May 11Wockhardt's (NSE:WOCKPHARMA) Strong Earnings Are Of Good QualityWhen companies post strong earnings, the stock generally performs well, just like Wockhardt Limited's ( NSE:WOCKPHARMA...
Reported Earnings • May 06Full year 2026 earnings released: EPS: ₹13.12 (vs ₹3.00 loss in FY 2025)Full year 2026 results: EPS: ₹13.12 (up from ₹3.00 loss in FY 2025). Revenue: ₹34.8b (up 15% from FY 2025). Net income: ₹2.13b (up ₹2.60b from FY 2025). Profit margin: 6.1% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 09Wockhardt Limited Files Marketing Authorisation Application for WCK 5222 with European Medicines AgencyWockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026. The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries-Iceland, Liechtenstein, and Norway-covering a total of 30 countries. Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA. Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections. Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation.
分析記事 • Dec 07Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 0.09% per year over the past 5 years.
分析記事 • Nov 10Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With RevenuesWockhardt Limited's ( NSE:WOCKPHARMA ) price-to-sales (or "P/S") ratio of 7.2x may look like a poor investment...
分析記事 • May 11Wockhardt's (NSE:WOCKPHARMA) Strong Earnings Are Of Good QualityWhen companies post strong earnings, the stock generally performs well, just like Wockhardt Limited's ( NSE:WOCKPHARMA...
Reported Earnings • May 06Full year 2026 earnings released: EPS: ₹13.12 (vs ₹3.00 loss in FY 2025)Full year 2026 results: EPS: ₹13.12 (up from ₹3.00 loss in FY 2025). Revenue: ₹34.8b (up 15% from FY 2025). Net income: ₹2.13b (up ₹2.60b from FY 2025). Profit margin: 6.1% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has increased by 116% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 09Wockhardt Limited Files Marketing Authorisation Application for WCK 5222 with European Medicines AgencyWockhardt has successfully filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic, WCK 5222, on 5 January 2026. The EMA is the regulatory authority responsible for the scientific evaluation, of new medicines across the 27 European Union (EU) Member States and three European Economic Area (EEA) countries-Iceland, Liechtenstein, and Norway-covering a total of 30 countries. Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), is eligible for Accelerated Assessment. This pathway allows for an abridged review timeline, reflecting the unmet medical need addressed by the product. The New Drug Application (NDA) on WCK 5222 is already under fast-track review by the US FDA. Based on the comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram negative infections across all countries under the EMA's jurisdiction. The priority review status granted to WCK 5222 underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections. Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation.
分析記事 • Dec 07Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 0.09% per year over the past 5 years.
分析記事 • Nov 10Wockhardt Limited's (NSE:WOCKPHARMA) Price Is Out Of Tune With RevenuesWockhardt Limited's ( NSE:WOCKPHARMA ) price-to-sales (or "P/S") ratio of 7.2x may look like a poor investment...
Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.81 (vs ₹1.47 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹4.81 (up from ₹1.47 loss in 2Q 2025). Revenue: ₹8.03b (flat on 2Q 2025). Net income: ₹780.0m (up ₹1.00b from 2Q 2025). Profit margin: 9.7% (up from net loss in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Aug 02Here's Why Wockhardt Limited's (NSE:WOCKPHARMA) CEO May Deserve A RaiseKey Insights Wockhardt will host its Annual General Meeting on 8th of August Salary of ₹24.1m is part of CEO Murtaza...
Reported Earnings • Jul 18Full year 2025 earnings released: ₹3.00 loss per share (vs ₹32.10 loss in FY 2024)Full year 2025 results: ₹3.00 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.4b (up 7.2% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 17Wockhardt Limited, Annual General Meeting, Aug 08, 2025Wockhardt Limited, Annual General Meeting, Aug 08, 2025, at 15:30 Indian Standard Time.
お知らせ • Jul 16+ 3 more updatesWockhardt Limited to Report Fiscal Year 2026 Results on May 30, 2026Wockhardt Limited announced that they will report fiscal year 2026 results on May 30, 2026
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change).
分析記事 • Jun 11Wockhardt Limited's (NSE:WOCKPHARMA) 26% Price Boost Is Out Of Tune With RevenuesWockhardt Limited ( NSE:WOCKPHARMA ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Jun 02Does Wockhardt (NSE:WOCKPHARMA) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • May 31Full year 2025 earnings released: ₹3.02 loss per share (vs ₹32.10 loss in FY 2024)Full year 2025 results: ₹3.02 loss per share (improved from ₹32.10 loss in FY 2024). Revenue: ₹30.7b (up 8.6% from FY 2024). Net loss: ₹470.0m (loss narrowed 90% from FY 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 77% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 23Wockhardt Limited to Report Q4, 2025 Results on May 29, 2025Wockhardt Limited announced that they will report Q4, 2025 results on May 29, 2025
New Risk • Apr 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 18% per year over the past 5 years.
お知らせ • Apr 07Wockhardt Looks to Exit US Generics BizWockhardt Limited (NSEI:WOCKPHARMA) is planning to exit the US generics business. Meanwhile, US consumers will have to bear the burden of tariffs, NDTV Profit reported. Habil Khorakiwala, Chairperson of Wockhardt, said, "There is a price pressure on US consumer and healthcare provider in the US. "As far as Wockhardt is concerned, we have around 5% presence in the US and we have planned to exit the US generic business," he said. Commenting on the pharmaceutical industry’s ability to manufacture products in the US, he said, “…will be very, very difficult for pharma to manufacture all products in the US because it will take several years to do that”. This comes amid US President Donald Trump's recent announcement on his administration's intention to impose unprecedented tariffs on pharmaceutical imports, signalling a shift from earlier exemptions under his reciprocal tariff policy. He clarified that pharmaceuticals would be treated as a separate category, with official announcements expected soon. This announcement follows his broader tariff measures, including a 26% duty on Indian imports and a universal 10% tariff on other goods, which were initially exempting pharmaceuticals.
分析記事 • Apr 02There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 25% Price JumpThose holding Wockhardt Limited ( NSE:WOCKPHARMA ) shares would be relieved that the share price has rebounded 25% in...
Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: ₹0.91 (vs ₹5.75 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.91 (up from ₹5.75 loss in 3Q 2024). Revenue: ₹7.29b (up 4.0% from 3Q 2024). Net income: ₹140.0m (up ₹970.0m from 3Q 2024). Profit margin: 1.9% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 03Wockhardt Limited to Report Q3, 2025 Results on Feb 07, 2025Wockhardt Limited announced that they will report Q3, 2025 results on Feb 07, 2025
New Risk • Jan 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
分析記事 • Dec 17What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling YouDespite an already strong run, Wockhardt Limited ( NSE:WOCKPHARMA ) shares have been powering on, with a gain of 31% in...
Reported Earnings • Nov 14Second quarter 2025 earnings released: ₹1.47 loss per share (vs ₹5.37 loss in 2Q 2024)Second quarter 2025 results: ₹1.47 loss per share (improved from ₹5.37 loss in 2Q 2024). Revenue: ₹8.18b (up 8.6% from 2Q 2024). Net loss: ₹220.0m (loss narrowed 71% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
お知らせ • Nov 09Wockhardt Limited to Report First Half, 2025 Results on Nov 13, 2024Wockhardt Limited announced that they will report first half, 2025 results on Nov 13, 2024
お知らせ • Nov 07Wockhardt Limited has filed a Follow-on Equity Offering.Wockhardt Limited has filed a Follow-on Equity Offering. Security Name: Equity Shares Security Type: Common Stock Price(minimum): INR 1162.25 Transaction Features: Regulation S; Subsequent Direct Listing
分析記事 • Nov 02Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch UpWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 29% gain in the last month...
お知らせ • Oct 12Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control OrganizationThe Subject Expert Committee (SEC) of Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has provided a favourable recommendation for Wockhardt's novel antibiotic MiqnafTM (nafithromycin) discovered and developed for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults. The SEC recommendation is based on CDSCO's comprehensive review of product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over last 15 years. A positive opinion from SEC of CDSCO would pave the way for gaining DCGI's final approval for MiqnafTM. MiqnafTM is globally, 1st-ever, Once-a-Day (OD) 3-days-only treatment for CABP patients including those caused by multi-drug resistant (MDR) bugs. The attractive feature of MiqnafTM is that it is highly active against azithromycin and amoxicillin/clavulanate resistant Pneumococci, as well as entire range of pathogens involved in such infections and thus offering a monotherapy option. Earlier, a lung penetration study conducted in the US demonstrated best-in-class lung concentrations of MiqnafTM enabling to evolve a convenient, compliance-friendly treatment for respiratory infections. MiqnafTM is expected to play a significant role in offering a reliable treatment option in the community and thus would obviate the need of hospitalization. Community-acquired pneumonia is the most common infection leading to hospitalization and deaths. Children and older adults are particularly vulnerable. Globally, 2.4 million annual deaths are caused by lower respiratory tract infections. India contributes to 23% of global community pneumonia burden.
お知らせ • Oct 07Wockhardt's WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I StudyWockhardt announced advancing the development of several new antibiotics aimed at combating difficult-to-treat drug-resistant bacterial infections that drive anti-microbial resistance (AMR) linked mortality and morbidity. Recently, one of its unique once-a-day, -lactam enhancer based MDR-active antibiotic, WCK 6777 (Ertapenem/Zidebactam) has successfully completed a Phase I study conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in US. Recognizing the therapeutic potential of WCK 6777 for infections caused by MDR Gram negative pathogens, DMID of NIH had selected this drug for Phase I studies. Zidebactam has already demonstrated promising safety profile in Phase I and on-going Phase II & III studies in combination with Cefepime (WCK 5222). Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI). WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient- parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections. Phase I study of WCK 6777 involved 52 participants and was designed as a double-blind, placebo-controlled, multiple-ascending dose trial in healthy volunteers. The trial rigorously assessed the safety and pharmacokinetics of WCK 6777, administering intravenous doses higher than the anticipated clinical dose over a period of 7 days. Results demonstrated a promising safety profile, with WCK 6777 (up to 3 grams + 3 grams daily) being well-tolerated, and no serious or unexpected adverse events reported. None of the subjects withdrew or were discontinued from the study due to treatment-related adverse events. Pharmacokinetic analysis revealed consistent exposure levels of both ertapenem and zidebactam, with no significant interactions when co-administered daily for the duration of the study. The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II /III clinical trials. Globally, incidence of UTI were 404.61 million with 236,790 deaths estimated in 2019. It is estimated that 1 in 100 of US adults will experience a cUTI each year, resulting in approximately 2.8 million cUTI cases and annualized total US costs in excess of $6 billion. There are 600,000 hospital admissions among adults for cUTIs each year in the United States with each episode costing an average of $9,441. Emerging therapeutic role of WCK 6777 makes it uniquely positioned to cater to the vast unmet need in the management of infections outside the hospital. About Ertapenem/Zidebactam (WCK 6777): Through independent studies, WCK 6777 is shown to be active against several carbapenem- resistant Gram-negative pathogens such as E. coli and Klebsiella including those producing metallo -lactamases, often encountered in community as well as hospital infections such as urinary tract infections (UTI). Other recently approved antibiotics do not address this issue. Owing to its activity against CDC/WHO/FDA categorized priority pathogens, WCK 6777 was granted a qualified infectious disease product (QIDP) designation in 2020 by U.S. FDA. About Wockhardt's New Drug Discovery portfolio: Over the period of 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA. Wockhardt's flagship novel mechanism based antibiotic, Zaynich (Cepefime/Zidebactam), designed to target extreme-drug resistant Gram negative infections, is undergoing a global Phase 3 study. Zaynich has already saved lives of >35 critically ill patients under compassionate use over last one year and is also being evaluated in a clinical study involving patients with documented meropenem-resistant infections. Clinical and Laboratory Standards Institute (CLSI), US has granted it a susceptibility breakpoint of 64 mg/L for 10 Gram negative pathogens showing high resistance rates, signifying strong potential to cover all the clinically important, extreme drug resistant Gram negative pathogens in seriously ill patients.
分析記事 • Aug 20What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling YouWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 27% gain in the last month...
Reported Earnings • Aug 10First quarter 2025 earnings released: ₹0.95 loss per share (vs ₹9.28 loss in 1Q 2024)First quarter 2025 results: ₹0.95 loss per share (improved from ₹9.28 loss in 1Q 2024). Revenue: ₹7.69b (up 19% from 1Q 2024). Net loss: ₹140.0m (loss narrowed 90% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
お知らせ • Aug 05Wockhardt Limited to Report Q1, 2025 Results on Aug 09, 2024Wockhardt Limited announced that they will report Q1, 2025 results on Aug 09, 2024
分析記事 • Jul 27Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jun 30Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedWockhardt Limited ( NSE:WOCKPHARMA ) shares have had a really impressive month, gaining 28% after a shaky period...
分析記事 • Jun 22Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO CompensationKey Insights Wockhardt to hold its Annual General Meeting on 28th of June CEO Murtaza Khorakiwala's total compensation...
お知らせ • Jun 08+ 1 more updateWockhardt Limited, Annual General Meeting, Jun 28, 2024Wockhardt Limited, Annual General Meeting, Jun 28, 2024, at 11:00 Indian Standard Time.
お知らせ • May 30Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) DirectorWockhardt Limited announced at the board meeting held on May 28, 2024, approved appointment of Amb. Ahmad Javed (DIN: 08668304) as an Additional (Independent) Director of the Company with effect from 28th May, 2024 and will hold office as an Additional Director of the Company until the upcoming 25th Annual General Meeting of the Company. Amb. Ahmad Javed, aged 68 years, is a distinguished former IPS officer of the 1980 batch Maharashtra cadre and a seasoned diplomat. With a robust educational foundation from St. Stephen's College, Delhi University, he has dedicated nearly four decades to law enforcement and public service. During his stint, Amb. Ahmad served as Commissioner of Police in Solapur City, New Mumbai, and Mumbai, and as Joint Commissioner of Police (Law & Order) in Mumbai. His notable diplomatic tenure includes serving as the Ambassador of India to Saudi Arabia from 2016 to2019. Amb. Ahmad's extensive experience encompasses law and order maintenance, crisis handling and management, Administration & HR, international relations, strategy and policy formulation and conflict resolution. Amb. Ahmad has been honoured with the Police Medal for Meritorious Service, President's Police Medal for Distinguished Service and Director General's Insignia. Currently, he contributes his expertise as an advisor and Independent Director to various organizations.
Reported Earnings • May 29Full year 2024 earnings released: ₹32.05 loss per share (vs ₹38.80 loss in FY 2023)Full year 2024 results: ₹32.05 loss per share (improved from ₹38.80 loss in FY 2023). Revenue: ₹28.8b (up 8.7% from FY 2023). Net loss: ₹4.63b (loss narrowed 17% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • May 23Wockhardt Limited to Report Q4, 2024 Results on May 28, 2024Wockhardt Limited announced that they will report Q4, 2024 results on May 28, 2024
お知らせ • Apr 04Wockhardt Limited Announces Cessation of Independent DirectorsWockhardt Limited announced that Dr. Sanjaya Baru, Mr. D S Brar and Mr. Aman Mehta ceased to be an Independent Directors of the Company on March 31, 2024, upon completion of their second term of five (5) consecutive years .
お知らせ • Mar 28Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion.Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 9,285,163 Price\Range: INR 517 Transaction Features: Regulation S; Subsequent Direct Listing
New Risk • Mar 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.6% operating cash flow to total debt). Earnings have declined by 24% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).
お知らせ • Mar 22Wockhardt Limited has filed a Follow-on Equity Offering.Wockhardt Limited has filed a Follow-on Equity Offering. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Subsequent Direct Listing
分析記事 • Feb 21Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%Despite an already strong run, Wockhardt Limited ( NSE:WOCKPHARMA ) shares have been powering on, with a gain of 29% in...
Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹5.75 loss per share (vs ₹6.62 loss in 3Q 2023)Third quarter 2024 results: ₹5.75 loss per share (improved from ₹6.62 loss in 3Q 2023). Revenue: ₹7.09b (up 1.4% from 3Q 2023). Net loss: ₹830.0m (loss narrowed 14% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
分析記事 • Dec 19There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price JumpWockhardt Limited ( NSE:WOCKPHARMA ) shares have continued their recent momentum with a 28% gain in the last month...
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.8% operating cash flow to total debt). Earnings have declined by 21% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
Reported Earnings • Nov 15Second quarter 2024 earnings released: ₹5.37 loss per share (vs ₹13.15 loss in 2Q 2023)Second quarter 2024 results: ₹5.37 loss per share (improved from ₹13.15 loss in 2Q 2023). Revenue: ₹7.77b (up 14% from 2Q 2023). Net loss: ₹770.0m (loss narrowed 59% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
分析記事 • Oct 14There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.4x Wockhardt Limited ( NSE:WOCKPHARMA ) is a stock worth...
Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Independent Director Amelia Fernandes was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 05Wockhardt Limited to Report Q1, 2024 Results on Aug 14, 2023Wockhardt Limited announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Jul 24Wockhardt Limited, Annual General Meeting, Aug 14, 2023Wockhardt Limited, Annual General Meeting, Aug 14, 2023, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon; to appoint a Director in place of Ms. Zahabiya Khorakiwala, who retires from office by rotation and, being eligible, offers herself for re-appointment; to consider ratification of remuneration payable to the Cost Auditors for the Financial Year 2023-24; to consider appointment of Ms. Amelia Fernandes as an Independent Director of the Company; to consider approval for re-appointment of Dr. Huzaifa Khorakiwala as an Executive Director and Fixation of Remuneration; and to consider approval for re-appointment of Dr. Murtaza Khorakiwala as Managing Director and Fixation of Remuneration.
お知らせ • May 20Wockhardt Limited to Report Q4, 2023 Results on May 26, 2023Wockhardt Limited announced that they will report Q4, 2023 results on May 26, 2023
Reported Earnings • Feb 14Third quarter 2023 earnings released: ₹6.62 loss per share (vs ₹0.61 loss in 3Q 2022)Third quarter 2023 results: ₹6.62 loss per share (further deteriorated from ₹0.61 loss in 3Q 2022). Revenue: ₹7.01b (down 18% from 3Q 2022). Net loss: ₹960.0m (loss widened ₹892.2m from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 04Wockhardt Limited to Report Q3, 2023 Results on Feb 13, 2023Wockhardt Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 7 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 06Second quarter 2023 earnings released: ₹13.15 loss per share (vs ₹3.03 profit in 2Q 2022)Second quarter 2023 results: ₹13.15 loss per share (down from ₹3.03 profit in 2Q 2022). Revenue: ₹7.36b (down 15% from 2Q 2022). Net loss: ₹1.89b (down ₹2.23b from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.
分析記事 • Jun 23Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Jun 02Full year 2022 earnings releasedFull year 2022 results: Revenue: (down 100% from FY 2021). Net income: (up ₹2.99b from FY 2021). Profit margin: (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Director Akhil Gupta was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Feb 18Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)Does the February share price for Wockhardt Limited ( NSE:WOCKPHARMA ) reflect what it's really worth? Today, we will...
Reported Earnings • Feb 01Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: ₹0.61 loss per share (down from ₹1.38 profit in 3Q 2021). Revenue: ₹8.56b (up 12% from 3Q 2021). Net loss: ₹67.8m (down 145% from profit in 3Q 2021). Revenue missed analyst estimates by 7.3%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • Jan 04Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Nov 11Second quarter 2022 earnings released: EPS ₹3.03 (vs ₹0.32 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹8.62b (up 21% from 2Q 2021). Net income: ₹335.3m (up ₹299.8m from 2Q 2021). Profit margin: 3.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 02Board Member recently bought ₹4.4m worth of stockOn the 25th of August, Akhilesh Krishna Gupta bought around 10k shares on-market at roughly ₹439 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹22m more in shares than they bought in the last 12 months.
分析記事 • Jul 26Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time BeingAs many shareholders of Wockhardt Limited ( NSE:WOCKPHARMA ) will be aware, they have not made a gain on their...
Executive Departure • Jul 23Company Secretary & Compliance Officer Gajanand Sahu has left the companyOn the 22nd of July, Gajanand Sahu's tenure as Company Secretary & Compliance Officer ended after 1.2 years in the role. We don't have any record of a personal shareholding under Gajanand's name. Gajanand is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.38 years.
Reported Earnings • Jul 10Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: ₹27.1b (down 4.8% from FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Jun 18Insider recently sold ₹20m worth of stockOn the 14th of June, Mahesh Patel sold around 30k shares on-market at roughly ₹658 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.
Reported Earnings • May 30Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)The company reported a poor full year result with increased losses and weaker control over costs, although revenues were flat. Full year 2021 results: Revenue: ₹28.4b (flat on FY 2020). Net loss: ₹2.99b (loss widened 83% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • May 18Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)In this article we are going to estimate the intrinsic value of Wockhardt Limited ( NSE:WOCKPHARMA ) by taking the...
Reported Earnings • Jan 30Third quarter 2021 earnings released: EPS ₹1.38 (vs ₹0.87 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: ₹8.65b (flat on 3Q 2020). Net income: ₹152.4m (up 58% from 3Q 2020). Profit margin: 1.8% (up from 1.1% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
分析記事 • Jan 26Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)In this article we are going to estimate the intrinsic value of Wockhardt Limited ( NSE:WOCKPHARMA ) by taking the...
Is New 90 Day High Low • Dec 30New 90-day high: ₹551The company is up 82% from its price of ₹303 on 01 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
Recent Insider Transactions • Dec 17Insider recently sold ₹1.6m worth of stockOn the 11th of December, Mahesh Patel sold around 3k shares on-market at roughly ₹536 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Is New 90 Day High Low • Dec 08New 90-day high: ₹487The company is up 73% from its price of ₹281 on 09 September 2020. The Indian market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.
分析記事 • Dec 01What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?Murtaza Khorakiwala has been the CEO of Wockhardt Limited ( NSE:WOCKPHARMA ) since 2009, and this article will examine...
Is New 90 Day High Low • Nov 20New 90-day high: ₹393The company is up 22% from its price of ₹322 on 21 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
